Business Wire

Vasion Appoints Transformational Leader Bob Pritchard as Chief Revenue Officer

Share

Vasion, Inc., a pioneer in serverless printing and orchestrated automation, today announced the appointment of Bob Pritchard as Chief Revenue Officer & President Global Sales, effective immediately. Pritchard brings a wealth of strategic experience to Vasion with a distinguished career in technology spanning over three decades, including award-winning success driving growth and delivering value for AI and process automation organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130298010/en/

Vasion, Inc., a pioneer in serverless printing and orchestrated automation, today announced the appointment of Bob Pritchard as Chief Revenue Officer & President Global Sales, effective immediately. (Photo: Business Wire)

“We are excited to welcome Bob to the team,” said Vasion CEO Ryan Wedig. “His deep expertise in the technology automation industry, coupled with his proven ability to build and lead successful revenue teams, will be invaluable as we continue to expand our market reach and deliver exceptional value to our customers.”

Pritchard joins Vasion from M-Files, where he served as Chief Revenue Officer during his three-year tenure. Prior to M-Files, Pritchard held various leadership roles for notable tech companies including Camunda, Alfresco Software (now Hyland Software), Redwood Software, OpenText, and IBM, demonstrating a consistent track record of success building high-performing sales organizations and driving revenue growth.

“Vasion has a compelling vision and a culture that deeply resonates with me. I am excited to leverage my experience in a market with limitless potential to help make digital transformation attainable for everyone,” said Bob Pritchard, Chief Revenue Officer & President Global Sales at Vasion. “We’ll continue to deliver exceptional value to our customers and partners by building on our proven, user-friendly platform and scaling our impact through focused execution.”

This appointment follows the departure of Jed Beck, who served as Chief Revenue Officer and Vice President at Vasion for six years. During his tenure, Beck successfully built a world-class sales organization and played a pivotal role in scaling significant revenue growth for the company.

About Vasion:

Vasion revolutionized print automation with a cloud-native SaaS solution and is now a leader in intuitive orchestrated automation. Organizations can simplify their digital transformation using Vasion’s automation platform to integrate their print output with the digital work teams do today: capturing data, applying AI, OCR and ICR, building and automating workflows, digital signatures, universal content storage and search, built-in compliance controls, and cloud-based Output Automation™, combining end user print and output management. Vasion accelerates digital transformation by enabling leaders to leverage advanced integrations for AI, with robust security in a Zero Trust environment, and integrating, directing, and analyzing their automations through a single platform. PrinterLogic® and Vasion® are registered trademarks, and Vasion Automate™, Vasion Output Management™, and Vasion Print™ are trademarks of Vasion in the United States and/or other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250130298010/en/

Contacts

Media Contact:
Nadia Romero
Sr. Manager of PR and Communications
nadia.romero@vasion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 15:30:00 EET | Press release

Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 15:00:00 EET | Press release

Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopot

REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release

Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a

Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye